Literature DB >> 11794488

The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes.

M Trojano1, D Paolicelli.   

Abstract

In the absence of pathognomonic clinical features or a definitive laboratory test, multiple sclerosis (MS) remains ultimately a diagnosis of exclusion. Accurate diagnosis is increasingly important with available disease modifying therapy. Unfortunately the rate of misdiagnosis remains around 5%-10%, indicating that 1 in 20 patients thought to have MS has, instead, a condition resembling MS. In this review we describe conditions that may be confused with MS because they can present as lesions disseminated in time, space, or both. Conditions often confused with MS may be inflammatory (systemic lupus erythematosus, Sjögren's syndrome, vasculitis, sarcoidosis, Behçet's disease), infectious (Lyme disease, syphilis, progressive multifocal leukoencephalopathy, HTLV-1 infection, herpes zoster), genetic (lysosomal disorders, adrenoleukodystrophy, mitochondrial disorders, CADASIL), metabolic (vitamin B12 deficiency), neoplastic (CNS lymphoma) and spinal (degenerative and vascular malformations) diseases. The key to the accurate diagnosis of MS is vigilance for atypical features, suggesting the possibility of an alternative diagnosis.

Entities:  

Mesh:

Year:  2001        PMID: 11794488     DOI: 10.1007/s100720100044

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  9 in total

1.  Central nervous system involvement in Sjogren's syndrome.

Authors:  F C Soliotis; C P Mavragani; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

2.  Improving outcomes in multiple sclerosis through early diagnosis and effective management.

Authors:  Emmanuelle Waubant
Journal:  Prim Care Companion CNS Disord       Date:  2012-10-25

3.  Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system.

Authors:  Yasuo Sasagawa; Takuya Akai; Osamu Tachibana; Hideaki Iizuka
Journal:  J Neurooncol       Date:  2014-09-26       Impact factor: 4.130

Review 4.  New and emerging immune-targeted drugs for the treatment of multiple sclerosis.

Authors:  Alan M Palmer
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

5.  The development of primary central nervous system B-cell lymphoma in multiple sclerosis.

Authors:  Mark K Lyons; Orland K Boucher; Barry D Birch; Naresh P Patel
Journal:  Neurohospitalist       Date:  2011-07

6.  A novel homozygous GALC variant has been associated with Krabbe disease in a consanguineous family.

Authors:  Feyza Nur Tuncer; Sibel Aylin Ugur Iseri; Zuhal Yapici; Mahmut Demir; Meryem Karaca; Mustafa Calik
Journal:  Neurol Sci       Date:  2018-09-12       Impact factor: 3.307

7.  Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study.

Authors:  Jay M Margolis; Robert Fowler; Barbara H Johnson; Cheryl A Kassed; Kristijan Kahler
Journal:  BMC Neurol       Date:  2011-10-06       Impact factor: 2.474

8.  Cognitive-constructivist Approach in Medical Settings: The Use of Personal Meaning Questionnaire for Neurological Patients' Personality Investigation.

Authors:  Barbara Poletti; Laura Carelli; Annalisa Lafronza; Federica Solca; Andrea Faini; Andrea Ciammola; Monica Grobberio; Vanessa Raimondi; Rita Pezzati; Rita B Ardito; Vincenzo Silani
Journal:  Front Psychol       Date:  2017-04-11

9.  Multiple sclerosis and the blood-central nervous system barrier.

Authors:  Alan M Palmer
Journal:  Cardiovasc Psychiatry Neurol       Date:  2013-01-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.